Raise closed, search for fresh raises on Seedstage

Centennial, CO

Developing a novel therapy to restore natural testosterone production and improve men’s health.

• Innovative therapy: Targets natural testosterone production without synthetic hormones.
• Strong leadership: Founded by a leading expert in steroid biochemistry with extensive research credentials.
• Patent protection: Drug pipeline protected by patents valid until 2040.
• Strategic growth plan: Plans to out-license technology and partner with pharmaceutical companies.
• Expanding market opportunity: Positioned to address additional conditions like diabetes and obesity linked to low testosterone.

Acesis Biomed is seeking to advance its innovative approach to treating low testosterone (Low-T) by developing a non-steroidal, oral therapy that stimulates the body’s natural testosterone production. Their solution is based on groundbreaking research by Dr. Vassilios Papadopoulos, a leading authority in steroid biochemistry, whose work has led to the creation of a drug pipeline of peptides targeting testosterone biosynthesis. Unlike traditional testosterone replacement therapies that introduce synthetic hormones, Acesis’s approach focuses on signaling the testis to restore natural testosterone levels, potentially offering a safer alternative with fewer side effects.

The company plans to use the funds raised to transition its lead drug candidate from preclinical studies to Phase I clinical trials, with the broader goal of out-licensing its technology to pharmaceutical partners for further development. Acesis also intends to explore additional indications for its therapy, including type 2 diabetes, obesity, and fatty liver disease, by forming strategic alliances and applying for non-dilutive grant funding. Through its novel solution and scalable business model, Acesis aims to reshape the testosterone replacement market and provide men with a more natural, effective treatment option for Low-T and related health conditions.

Company Info

Acesis Biomed develops non-steroidal peptide-based treatments aimed at naturally restoring testosterone levels in men.

Acesis Biomed is a biopharmaceutical company focused on developing a novel non-steroidal treatment for low testosterone (low-T) in men. The company’s lead solution utilizes short peptides to stimulate the body’s natural testosterone production, avoiding the synthetic hormone approach of traditional testosterone replacement therapies. This innovation stems from the research of Dr. Vassilios Papadopoulos, a recognized expert in steroid biochemistry whose discoveries have led to a new mechanism of action targeting testosterone biosynthesis. Acesis holds two patent families protecting its drug pipeline, with patents extending until 2040 in the U.S., and aims to provide a potentially safer, more natural treatment alternative to men suffering from hypogonadism and related conditions.

Acesis’s business model centers on advancing its drug pipeline through preclinical studies, clinical trials, and ultimately forming strategic partnerships with pharmaceutical companies. The company plans to out-license its treatment after Phase I trials and potentially expand into other indications like type 2 diabetes, obesity, and non-alcoholic fatty liver disease. The low testosterone market, currently valued at $2.04 billion, is expected to grow steadily due to increasing prevalence and unmet needs in men’s health. Acesis positions itself as a differentiator in the market with its approach to restoring testosterone naturally, which may address safety concerns associated with conventional therapies and unlock opportunities for treating related diseases.